NVS News and Press, Novartis AG From 05/13/24

2024-05-13 17:41:32 ET More on Voyager Therapeutics Voyager Therapeutics: On Track To Deliver High Returns On Investment Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcr...

2024-05-11 10:00:00 ET More on STOXX Europe 600 Index: Dollar Is Softer Ahead Of The Employment Report Japan Drives Home Message Yen Retreats, While Stronger EMU GDP Underscores Nascent Recovery And Lifts The Euro Five reasons to prefer the European market vs...

2024-05-08 12:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...

2024-05-05 14:25:00 ET There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common th...

2024-05-05 09:45:00 ET Summary Lantheus Holdings just posted strong Q1 numbers, exceeding expectations and confirming its attractive investment potential. The firm is delivering solid revenue growth, impressive free cash flow, and management raised FY2024 guidance significantly. ...

2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte

2024-05-03 11:15:29 ET Summary Swiss Helvetia Fund is trading at a 16% discount to NAV and could be a potential takeover target in the future. The ETF has concentrated holdings in strong businesses with high dividends, making it attractive for dividend investors. The overall d...

2024-05-03 09:53:55 ET Summary TG Therapeutics beat first quarter revenue expectations and raised the full-year revenue guidance by $40 million at the mid-point. Work on the subcutaneous version of Briumvi continues and could represent the next step for increased long-term growth ...

2024-05-03 07:00:00 ET Summary The stock market is unpredictable, and even professionals struggle to understand it. Stocks have historically been the best-performing asset, but short-term returns are influenced by sentiment, momentum, and luck. According to JPMorgan, 96% of st...